

Disclosures

Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Alnylam	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Amicus	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Idorsia	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Pfizer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer	Other - Trial Steering Committee	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sanofi/Genzyme	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Shire HGT	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

Personal Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Cardiomyopathy UK	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Heart Failure and Cardiomyopathies
European Society of Cardiology	Other - Chairman ESC Academy	None (\$0)	Heart Failure and Cardiomyopathies
European Society of Cardiology	Other - Chairman ESC Guideline on Hypertrophic Cardiomyopathy 2012-14	None (\$0)	Heart Failure and Cardiomyopathies

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation	Array Pharma	
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy	MyoKardia	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/22/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/22/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/22/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/22/2018

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.